Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of midostaurin in vivo

Clinical Cancer Research

Volumn 14, Issue 17, 2008, Pages 5400-5409

  Brounais, Bénédicte ^a,b   Chipoy, Céline ^a,b   Mori, Kanji ^a,b   Charrier, Céline ^a,b   Battaglia, Séverine ^a,b   Pilet, Paul ^c   Richards, Carl D ^d   Heymann, Dominique ^a,b   Rédini, Françoise ^a,b   Blanchard, Frédéric ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Universite de Nantes   (France)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; MIDOSTAURIN; ONCOSTATIN M; 4'-N-BENZOYLSTAUROSPORINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; STAUROSPORINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE TUMOR; CANCER INHIBITION; CANCER SURVIVAL; CELL ADHESION; CELL MOTILITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; GENE TRANSFER; HISTOPATHOLOGY; LUNG METASTASIS; MALE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOSARCOMA; PRIORITY JOURNAL; RAT; TISSUE REPAIR; TRABECULAR BONE; TUMOR NECROSIS; ANIMAL; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BONE RESORPTION; CELL LINE, TUMOR; MALE; ONCOSTATIN M; OSTEOSARCOMA; RATS; RATS, SPRAGUE-DAWLEY; STAUROSPORINE;

EID: 53049108932     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4781     Document Type: Article

References (46)

1. Fuchs B, Pritchard DJ. Etiologyofosteosarcoma. Clin Orthop Relat Res 2002;397:40-52.
2. 1 to S-phase cell cycle checkpoint is involved in the pathogenesis of human osteosarcoma. Diagn Mol Pathol 2004;13:81-91.
3. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84.
4. LamoureuxF,TrichetV, Chipoy C, Blanchard F, Gouin F, Redini F. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther 2007;7:169 -81.
5. Heymann D, Rousselle AV. gp130 cytokine family and bone cells. Cytokine 2000;12:1455-68.
6. Liu XH, Kirschenbaum A, Yao S, Levine AC. The role of the interleukin-6/gp130 signaling pathway in bone metabolism. Vitam Horm 2006;74:341-55.
7. Wong PK,Campbell IK, Egan PJ, Ernst M, Wicks IP. The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheum 2003;48:1177-89.
8. Franchimont N,Wertz S,Malais,M.Interleukin-6: an osteotropic factor influencing bone formation? Bone 2005;37:601-6.
9. Kitamura H, Kawata H,Takahashi F, Higuchi Y, Furuichi T,Ohkawa H. Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. A cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow. Am J Pathol 1995;147:1682-92.
10. De Benedetti F, Rucci N, Del Fattore A, et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 2006;54:3551-63.
11. Richards CD. Matrix catabolism in arthritis: priming the guns with oncostatin M. J Rheumatol 2004;31:2326-8.
12. Hui W, Cawston TE, Richards CD, Rowan AD. A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL. Arthritis Res Ther 2005;7:R57-64.
13. de Hooge AS, van de Loo FA, Bennink MB, et al. Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-κB ligand. Am J Pathol 2002;160:1733-43.
14. Malaval L, Liu F, Vernallis AB, Aubin JE. GP130/OSMRis the only LIF/IL-6 family receptor complex to promote osteoblast differentiation of calvaria progenitors. J Cell Physiol 2005;204:585-93.
15. Chipoy C, Berreur M, Couillaud S, et al. Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCδ and STAT3. J Bone Miner Res 2004;19:1850-61.
16. BellidoT, O'Brien CA, Roberson PK, Manolagas SC. Transcriptional activation of the p21(WAF1,CIP1,SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem 1998;273:21137-44.
17. Chipoy C, Brounais B, Trichet V, et al. Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53. Oncogene 2007;26:6653-64.
18. Sosman JA, Aronson FR, Sznol M, et al. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. Clin Cancer Res1997;3:39-46.
19. Ding C, Jones G. Technology evaluation: MRA,Chugai. Curr Opin Mol Ther 2003;5:64-9.
20. Mule JJ, McIntosh JK, Jablons DM, Rosenberg SA. Antitumor activity of recombinant interleukin 6 in mice. J Exp Med 1990;171:629-36.
21. Ouyang L, Shen LY, Li T, Liu J. Inhibition effect of oncostatin M on metastatic human lung cancer cells 95-D in vitro and on murine melanoma cells B16BL6 in vivo. Biomed Res 2006;27:197-202.
22. Nagai Y, Yamato H, Akaogi K, et al. Role of interleukin-6 in uncoupling of bone in vivo in a human squamous carcinoma coproducing parathyroid hormone-related peptide and interleukin-6. J Bone Miner Res 1998;13:664-72.
23. Morgan H, TumberA, Hill PA. Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte/macrophage colony-stimulating factor. Int J Cancer 2004;109:653-60.
24. 2 and leukemia inhibitory factor and supports osteoclast formation in vitro via a stromal cell-dependent pathway. J Bone Miner Res 1998;13:400-8.
25. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006;12:6213-6s.
26. Kwan Tat S, Padrines M, Theoleyre S, Heymann D, FortunY. IL-6, RANKL,TNF-α/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004;15:49-60.
27. Fabbro D, Ruetz S, Bodis S, et al. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000;15:17-28.
28. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respondto asmall-moleculeFLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105:54-60.
29. Kerr C, Langdon C, Graham F, Gauldie J, Hara T, Richards CD. Adenovirus vector expressing mouse oncostatin M induces acute-phase proteins and TIMP-1 expression in vivo in mice. J Interferon Cytokine Res1999;19:1195-205.
30. Guillot C, Coathalem H, Chetritt J, et al. Lethal hepatitis after gene transfer of IL-4 in the liver is independent of immune responses and dependent on apoptosis of hepatocytes: a rodent model of IL-4-in-duced hepatitis. J Immunol 2001;166:5225-35.
31. Heymann D, Ory B, Blanchard F, et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 2005;37:74-86.
32. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
33. Ganjavi H, Gee M, NarendranA, et al. Adenovirus- mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther 2006;13:415-9.
34. Ludeman SM. The chemistry of the metabolites of cyclophosphamide. Curr Pharm Des 1999;5:627-43.
35. Jorcyk CL, Holzer RG, Ryan RE. Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells. Cytokine 2006;33:323-36.
36. Ozbek S, Peters M, Breuhahn K, et al. The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells. Oncogene 2001;20:972-9.
37. Palmqvist P, Persson E, Conaway HH, Lerner UH. IL- 6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-κB ligand, osteoprotegerin, and receptor activator of NF-κB in mouse calvariae. J Immunol 2002;169:3353-62.
38. Tanaka M, Hara T, Copeland NG, Gilbert DJ, Jenkins NA, Miyajima A. Reconstitution of the functional mouse oncostatin M (OSM) receptor: molecular cloning of the mouse OSM receptor β subunit. Blood 1999;93:804-15.
39. Bellido T, Borba VZ, Roberson P, Manolagas SC. Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology 1997;138:3666-76.
40. Sims NA, Jenkins BJ, Quinn JM, et al. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest 2004;113:379-89.
41. Sims NA, Walker EC, McGregor NE, Poulton IJ, Gillespie MT, Martin TJ. Oncostatin M is an essential regulator of bone formation, adipogenesis and osteoclastogenesis. Bone 2007;40:S126.
42. Dillon SR, Sprecher C, Hammond A, et al. Inter-leukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004;5:752-60.
43. Scaffidi AK, Mutsaers SE, Moodley YP, et al. Oncostatin M stimulates proliferation, induces collagen production and inhibits apoptosis of human lung fibroblasts. Br J Pharmacol 2002;136:793-801.
44. Langdon C, Kerr C, Tong L, Richards CD. Oncostatin M regulates eotaxin expression in fibroblasts and eosinophilic inflammation in C57BL/6 mice. J Immunol 2003;170:548-55.
45. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002;1:433-43.
46. Zaugg K, Rocha S, Resch H, et al. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412. Cancer Res 2001;61:732-8.